Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Medical oncology

Optimizing chemotherapy and radiotherapy for anaplastic glioma

Nature Reviews Clinical Oncology volume 7, pages 428–430 (2010)Cite this article

Subjects

The optimum approach for the treatment of rare anaplastic gliomas following surgical resection is uncertain. A recent study has now provided a greater understanding of the heterogeneous tumor biology of these tumors and has emphasized the prognostic importance of chromosome 1p19q deletion, IDH mutation and MGMT promoter methylation. The importance of radiotherapy and chemotherapy for treating these heterogeneous tumors is being elucidated for subgroups of patients.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459–466 (2009).

    Article  CAS  Google Scholar 

  2. van den Bent, M. J. et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organization for Research and Treatment of Cancer phase III trial. J. Clin. Oncol. 24, 2715–2722 (2006).

    Article  CAS  Google Scholar 

  3. Cairncross, G. et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial. J. Clin. Oncol. 24, 2707–2714 (2006).

    Article  CAS  Google Scholar 

  4. Wick, W. et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol. 27, 874–880 (2009).

    Article  Google Scholar 

  5. van den Bent, M. J. et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin. Cancer Res. 16, 1597–1604 (2010).

    Article  CAS  Google Scholar 

  6. DeAngelis, L. M. Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected]. J. Clin. Oncol. 27, 861–862 (2009).

    Article  Google Scholar 

  7. Cairncross, G. et al. A randomized trial of chemotherapy plus radiotherapy (RT) versus RT alone for anaplastic oligodendroglioma (RTOG 9402): the perspective of longer follow-up [abstract 16]. Int. J. Radiat. Oncol. Biol. Phys. 72, S7–S8 (2008).

    Article  Google Scholar 

  8. Abrey, L. E. et al. Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro-oncol. 9, 314–318 (2007).

    Article  CAS  Google Scholar 

  9. US National Library of Medicine. ClinicalTrials.gov [online], (2010).

  10. US National Library of Medicine. ClinicalTrials.gov [online], (2010).

Download references

Author information

Authors and Affiliations

  1. Department of Neurology and Brain Tumor Center, Memorial Sloan–Kettering Cancer Center, 1275 York Avenue, New York, 10065, NY, USA

    Patrick G. Morris & Andrew B. Lassman

Authors
  1. Patrick G. Morris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew B. Lassman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew B. Lassman.

Ethics declarations

Competing interests

P. G. Morris has received honoraria from the following companies: Eisai, Genomic Health, Pfizer, Haymarket Media Group, Bristol-Myers Squibb, Genentech, Novartis and Centocor Ortho Biotech. A. B. Lassman acts as a consultant for, and has received honoraria and research support from, Merck & Co. He has received research support from Keryx Biopharmaceuticals, Sigma Tau Pharmaceuticals and Genentech and acts as a consultant for Genentech, Eisai, ImClone and Cephalon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morris, P., Lassman, A. Optimizing chemotherapy and radiotherapy for anaplastic glioma. Nat Rev Clin Oncol 7, 428–430 (2010). https://doi.org/10.1038/nrclinonc.2010.98

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2010.98

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer